Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
entecavir + Fuzheng Huayu
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Entecavir + Fuzheng Huayu is a combination therapy consisting of entecavir, a nucleoside analog antiviral agent that inhibits hepatitis B virus (HBV) DNA polymerase, and Fuzheng Huayu (FZHY), a traditional Chinese herbal formula. This combination is primarily investigated for the treatment of chronic hepatitis B patients with significant liver fibrosis or cirrhosis. Clinical studies have shown that adding Fuzheng Huayu to standard entecavir therapy results in higher rates of necroinflammatory improvement and regression of liver fibrosis compared to entecavir alone[1][2][4]. The mechanism involves direct antiviral activity from entecavir and antifibrotic as well as hepatoprotective effects from the herbal components in FZHY. The combination may also reduce the risk of progression to hepatocellular carcinoma in certain patient subgroups[4].
- Other names
- entecavir + FZHYETV + FZHYentecavir plus Fuzheng HuayuETV plus FZHY
02
Targets
HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on entecavir + Fuzheng Huayu.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on entecavir + Fuzheng Huayu.